跳至主要内容
临床试验/NCT05694455
NCT05694455已完成不适用

Clinical Utility of Longitudinal Measurement of Hemodynamic Incoherence and Endothelial

Denver Health and Hospital Authority2 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2022年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
68
试验地点
2
主要终点
Initiation and Duration Renal Replacement Therapy

研究概览

简要总结

Purpose: To assess the prognostic role of Handheld Vital Microscopy (HVM) and evaluate levels of endothelial glycocalyx (eGC) breakdown in patients demonstrating Hemodynamic Incoherence (HI), to elucidate a mechanistic link between the eGC and HI in order to inform prognostic enrichment of future resuscitation trials. We will serially evaluate microhemodynamics (MiH) and macro hemodynamics (maH) and the perfused boundary region (PBR, an visual proxy for eGC thickness) using HVM, and a validated circulating biomarker of eGC integrity.

详细描述

There are few reliable prognostic indicators in early sepsis to predict disease progression, in part because the pathophysiologic mechanism of vascular dysregulation remains incompletely understood. The global Coronavirus Disease 2019 (COVID-19) pandemic has increased the number of patients with sepsis, straining hospital systems and illustrating the need for research into prognostic and therapeutic strategies. An important area of research is the role of the eGC, a thin vascular lining composed of proteoglycans, glycosaminoglycan side-chains, and plasma proteins that play a central role in microvascular homeostasis, the function of which is compromised in sepsis. Another growing field of inquiry is the phenomenon of HI, a condition in which MiH remain dysfunctional despite normalization of conventionally targeted MaH measures such as mean arterial pressure (MAP), leading to poor end-organ perfusion. It has been hypothesized that HI due to persistently deranged MiH and reduced end-organ perfusion result in an ongoing state of "microvascular shock", leading to worsening end-organ damage despite apparent normalization of conventionally targeted parameters. Importantly, HI has been shown to predict poor patient outcomes, with abnormal MiH predicting patient mortality despite normalization of MAP after administration of vasoactive medications. MiH measures have also been shown to differ significantly between septic patients and healthy controls. In one study of a large sepsis cohort, MiH parameters were predictive of adverse outcomes, while MaH parameters were not, suggesting that MiH measurements, and HI in particular may be more sensitive than conventional measures for predicting outcomes in sepsis. One hypothesis is that HI in sepsis is mediated by degradation of the eGC, with subsequent loss of microvascular homeostasis, though the role of the eGC as a vascular barrier remains controversial.

One question that remains is whether or not microvascular changes can predict patient outcomes in patients judged to be adequately fluid resuscitated, as measured by MAP or Starling Stroke Volume/Non-invasive cardiac monitor (NICOM) testing.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Septic Patient Cohort:
  • Greater than or equal to 18 years of age
  • Diagnosed with sepsis or septic shock
  • Require admission to the Hospital
  • Control Cohort:
  • Greater than or equal to 18 years of age
  • Undergoing elective surgery requiring intubation and general anesthesia

排除标准

  • Patients with any of the following characteristics will be excluded
  • Less than 18 years old
  • Chronic Kidney disease on dialysis
  • Currently pregnant
  • Incarcerated persons
  • Control Cohort:
  • Less than 18 years old
  • History of Chronic Kidney disease on dialysis, uncontrolled diabetes, cirrhosis, heart failure, or nephritic or nephrotic syndromes.
  • Currently pregnant
  • Incarcerated persons

研究组 & 干预措施

Septic Patient Interventions

Other

Septic Patients will have all interventions performed: Urine collection, Passive Leg Raise, Ultrasound and sublingual microscopy

干预措施: Starling Stroke Volume (Starling SV)- Passive Leg Raise (Diagnostic Test)

Septic Patient Interventions

Other

Septic Patients will have all interventions performed: Urine collection, Passive Leg Raise, Ultrasound and sublingual microscopy

干预措施: Microscan Sublingual Microscopy (Diagnostic Test)

Septic Patient Interventions

Other

Septic Patients will have all interventions performed: Urine collection, Passive Leg Raise, Ultrasound and sublingual microscopy

干预措施: Venous Excess Ultrasound Scoring (VExUS) (Diagnostic Test)

Control Patient Interventions

Other

Control patients will have urine collection and sublingual microscopy performed when intubated

干预措施: Starling Stroke Volume (Starling SV)- Passive Leg Raise (Diagnostic Test)

Control Patient Interventions

Other

Control patients will have urine collection and sublingual microscopy performed when intubated

干预措施: Urine Collection (Other)

Septic Patient Interventions

Other

Septic Patients will have all interventions performed: Urine collection, Passive Leg Raise, Ultrasound and sublingual microscopy

干预措施: Urine Collection (Other)

结局指标

主要结局

Initiation and Duration Renal Replacement Therapy

时间窗: 90 day

Renal Replacement Therapy will be monitored while hospitalized for Sepsis/Septic Shock for initiation and days receiving Renal replacement will be counted.

次要结局

  • Rate of Inpatient Mortality(90 day)
  • Rate of 90 day survival(90 day)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ivor Douglas

Chief Pulmonary Critical Care

Denver Health and Hospital Authority

研究点 (2)

Loading locations...

相似试验